8WK.F ABERA BIOSCIENCE AB

Healthcare Biotechnology Frankfurt Exchange
0.6040 EUR
Close of Nov 11, 2026
0.4520 0.8380
Market cap
EUR 13.0M
P/E
-
P/B
8.01x
ROE
-126.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8WK.F undervalued?

Graham number

The Graham number of ABERA BIOSCIENCE AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABERA BIOSCIENCE AB fundamental analysis

No fundamental analysis for ABERA BIOSCIENCE AB yet.

ABERA BIOSCIENCE AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABERA BIOSCIENCE AB

Abera Bioscience AB (publ), a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETE…

Full company profile